New Ultra-Widefield Retinal Imaging Device for General Ophthalmologists

Optos plc unveils the 200Tx™, its newest ultra-widefield retinal imaging device. Designed specifically for general ophthalmologists and vitreo-retinal specialists (who focus on treating diseases of the vitreous and retina) the device supports the diagnosis, analysis, documentation and monitoring of ocular pathology in the periphery of the retina. The Optos 200Tx was exhibited for the first time at the American Academy of Ophthalmology (AAO) meeting.

The 200Tx is the first imaging device that provides visualisation of ultra-widefield autofluorescence changes to retinal pigment epithelium (RPE), the pigmented cell layer just outside the neurosensory retina that nourishes retinal visual cells. The study of such cellular changes is central to the management of diseases such as age related macular degeneration (AMD). The 200Tx offers multiple wavelength
imaging including options for colour, red-free, fluorescein angiography and autofluorescence, each of which can reveal different pathologies. The device also provides simultaneous pole to periphery views of more than 80% or 200 degrees of the retina in a single capture, helping physicians discover evidence of disease and guide treatment decisions.

A promising study in AMD led by Srinivas Sadda M.D, of the Doheny Eye Institute, University of Southern California using the 200Tx device was recently presented at the American Academy of Retina Specialists Meeting. The study found that 76% of eyes in patients with AMD had peripheral abnormalities, and the addition of auto-fluorescence capability to retinal scanning technologies was seen to aid in the detection of AMD.

The 200Tx will also be used to determine the frequency and significance of peripheral retinal abnormalities as part of the Age-Related Eye Disease Study 2 (AREDS2), which is being conducted to determine methods of slowing the progression of vision loss from AMD.